Effect of Pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis

This publication has 38 references indexed in Scilit:

• Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats
  Atherosclerosis, 1988
• Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects
  Atherosclerosis, 1988
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia
  Metabolism, 1987
• Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
  JAMA, 1986
• CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
• Status of the coronary arteries in the nephrotic syndrome
  The American Journal of Medicine, 1977
• ISCHÆMIC HEART-DISEASE COMPLICATING NEPHROTIC SYNDROME
  The Lancet, 1969
• ISCHIEMIC HEART-DISEASE AS A COMPLICATION OF NEPHROTIC SYNDROME
  The Lancet, 1969
• Determination of total protein in spinal fluid with sulphosalicylic acid and trichloroacetic acid
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1960